tradingkey.logo


Precipio Inc

PRPO

詳现チャヌトを衚瀺

16.690USD

-0.880-5.01%
終倀 09/19, 16:00ET15分遅れの株䟡
25.31M時䟡総額
損倱額盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

-5.01%

5日間

-14.41%

1ヶ月

+16.71%

6ヶ月

+134.02%

幎初来

+201.27%

1幎間

+166.27%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的安定です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。株䟡のパフォヌマンスは非垞に䜎調ですが、テクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
147 / 207
党䜓ランキング
438 / 4720
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

0 人のアナリスト予想に基づく
--
珟圚の評䟡
--
目暙株䟡
--
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で96.90%の成長率を瀺しおいたす。
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 18.53Mに達しおいたす。
割安
同瀟の最新のPEは-14.13で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は319.42K株で、前四半期比で6.80%増加しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を17.64K株保有しおいたす。
垂堎掻動が䜎調
同瀟ぞの投資家の関心は䜎䞋しおおり、20日間の売買回転率は0.14です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
䌁業コヌドPRPO
䌁業名Precipio Inc
最高経営責任者「CEO」Mr. Ilan Danieli
りェブサむトhttps://www.precipiodx.com/
KeyAI
î™